Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats
Open accessAbstract
Nociceptin/orphanin FQ peptide (NOP) receptor agonists attenuate morphine-induced conditioned place preference in rodents. However, it is not known whether NOP agonists have reinforcing properties or can inhibit mu opioid receptor (MOP)-mediated reinforcement as measured by drug self-administration in rodents. Further understanding the behavioral effects of NOP agonists could suggest them as having potential in attenuating reinforcing effects of opioids. In the first part of the study, reinforcing properties of selective NOP agonist SCH221510 were determined and compared with the full MOP agonist remifentanil under fixed-ratio 5 (FR5) and progressive-ratio (PR) schedules of drug self-administration. In the second part, effects of systemic and intracisternal pretreatment of SCH221510 were determined and compared with MOP antagonist naltrexone in attenuating reinforcing effects of remifentanil and a non-drug reinforcer (sucrose pellets). Remifentanil self-administration (0.3-10 µg/kg/infusion) generated a biphasic dose-response curve, characteristic of drugs with reinforcing properties. SCH221510 (3-300 µg/kg/infusion) self-administration resulted in flat dose-response curves and early break-points under the PR, indicative of drugs lacking reinforcing value. Intracisternally, but not systemically, administered SCH221510 (0.3-3 µg) attenuated remifentanil self-administration, comparable with systemic naltrexone (0.03-0.3 mg/kg). SCH221510 (1-3 µg), unlike naltrexone (0.03-1 mg/kg), attenuated responding for sucrose pellets. Both effects of SCH221510 were reversed by the NOP antagonist J-113397 (0.3-3 µg). These results suggest that SCH221510 does not function as a reinforcer in rats, and that it can attenuate the reinforcing value of MOP agonists; therefore, the potential utility of NOP agonists for the treatment of drug addiction warrants further evaluation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Conditioned place preference: what does it add to our preclinical understanding of drug reward?
Bardo, M. T., & Bevins, R. A. (2000) · Psychopharmacology · doi:10.1007/s002130000569 · Cited by 1,233 · see citing works
The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential
Lambert, D. G. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2572 · Cited by 361 · see citing works
A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat
Jenck, F., Wichmann, J., Dautzenberg, F. M., Moreau, J., Ouagazzal, A., Martin, J. R., Lundstrom, K. H., Cesura, A. M., Poli, S. M., Roever, S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090514397 · Cited by 275 · see citing works
Controversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270 · see citing works
Carter, L. P., & Griffiths, R. R. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.003 · Cited by 208 · see citing works
Witkin, J. M., Statnick, M. A., Rorick‐Kehn, L. M., Pintar, J. E., Ansonoff, M. A., Chen, Y., Tucker, R. C., & Ciccocioppo, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.011 · Cited by 197 · see citing works
The predictive validity of the rat self-administration model for abuse liability
O’Connor, E. C., Chapman, K. L., Butler, P., & Mead, A. N. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.012 · Cited by 191 · see citing works
Amygdala-Dependent Fear Is Regulated by Oprl1 in Mice and Humans with PTSD
Andero, R., Brothers, S. P., Jovanović, T., Chen, Y. T., Salah-Uddin, H., Cameron, M. D., Bannister, T. D., Almli, L. M., Stevens, J. S., Bradley, B., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005656 · Cited by 152 · see citing works
The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion
Devine, D. P., Reinscheid, R. K., Monsma, F. J., Civelli, O., & Akil, H. (1996) · Brain Research · doi:10.1016/0006-8993(96)00476-3 · Cited by 145 · see citing works
Likeability and Abuse Liability of Commonly Prescribed Opioids
Wightman, R., Perrone, J., Portelli, I., et al. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-012-0263-x · Cited by 139 · see citing works
Schröder, W., Lambert, D. G., Ko, M., & Koch, T. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12744 · Cited by 128 · see citing works
Self-citationShannon, H. E., & Lutz, E. A. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(01)00173-3 · Cited by 123 · see citing works
Chuck, T. L., McLaughlin, P. J., Arizzi-LaFrance, M. N., et al. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.045 · Cited by 99 · see citing works
Ko, M., Woods, J. H., Fantegrossi, W. E., Galuska, C. M., Wichmann, J., & Prinssen, E. P. M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.33 · Cited by 97 · see citing works
Self-citationCremeans, C. M., Gruley, E., Kyle, D. J., & Ko, M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194308 · Cited by 97 · see citing works
Self-citationGiannuario, A. D., Pieretti, S., Catalani, A., & Loizzo, A. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00579-0 · Cited by 95 · see citing works
Giannuario, A. D., & Pieretti, S. (2000) · Peptides · doi:10.1016/s0196-9781(00)00250-3 · Cited by 90 · see citing works
Varty, G. B., Hyde, L. A., Hodgson, R. A., Lu, S. X., McCool, M. F., Kazdoba, T. M., Vecchio, R. A. D., Guthrie, D. H., Pond, A. J., Grzelak, M. E., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0041-4 · Cited by 86 · see citing works
Varty, G. B., Lu, S. X., Morgan, C. A., Cohen-Williams, M. E., Hodgson, R. A., Smith‐Torhan, A., Zhang, H., Fawzi, A. B., Graziano, M. P., Ho, G. D., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136937 · Cited by 81 · see citing works
Remifentanil and Other Opioids
Servin, F. S., & Billard, V. (2008) · Springer eBooks · doi:10.1007/978-3-540-74806-9_14 · Cited by 79 · see citing works
The Nociceptin/Orphanin FQ Receptor (NOP) as a Target for Drug Abuse Medications
Zaveri, N. T. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795371341 · Cited by 75 · see citing works
Lin, A. P., & Ko, M. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300124f · Cited by 75 · see citing works
Self-citationSpinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat
Obara, I., Przewłocki, R., & Przewłocka, B. (2005) · Pain · doi:10.1016/j.pain.2005.03.012 · Cited by 69 · see citing works
Sukhtankar, D. D., Zaveri, N. T., Husbands, S. M., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203984 · Cited by 58 · see citing works
Self-citationKawahara, Y., Kaneko, F., Yamada, M., Kishikawa, Y., Kawahara, H., & Nishi, A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.022 · Cited by 57 · see citing works
Collins, G. T., & Woods, J. H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123042 · Cited by 57 · see citing works
Cooper, Z. D., Truong, Y. N., Shi, Y., & Woods, J. H. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139196 · Cited by 52 · see citing works
Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens
Taber, M. T., Zernig, G., & Fibiger, H. C. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01124-4 · Cited by 40 · see citing works
Podlesnik, C. A., Ko, M.-C., Winger, G., Wichmann, J., Prinssen, E. P., & Woods, J. H. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2012-7 · Cited by 40 · see citing works
Self-citationRutten, K., Vry, J. D., Bruckmann, W., et al. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.10.004 · Cited by 40 · see citing works
Comparative Abuse Liability of Intravenously Administered Remifentanil and Fentanyl
Baylon, G. J., Kaplan, H. L., Somer, G. R., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00002 · Cited by 39 · see citing works
O’Connor, E. C., & Mead, A. N. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.05.018 · Cited by 38 · see citing works
Sukhtankar, D. D., Lee, H., Rice, K. C., & Ko, M. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3341-0 · Cited by 35 · see citing works
Self-citationThe orphanin receptor agonist RO 64-6198 does not induce place conditioning in rats
Pen, G. L., Wichmann, J., Moreau, J., et al. (2002) · Neuroreport · doi:10.1097/00001756-200203250-00018 · Cited by 34 · see citing works
Lee, H., Naughton, N. N., Woods, J. H., et al. (2003) · Behavioural Pharmacology · doi:10.1097/00008877-200311000-00002 · Cited by 33 · see citing works
Crespo, J. A., Stöckl, P., Zorn, K., Saria, A., & Zernig, G. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.48 · Cited by 28 · see citing works
Calò, G., & Guerrini, R. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch015 · Cited by 28 · see citing works
Research and Development of Opioid-Related Ligands
Ko, M., & Husbands, S. M. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131 · Cited by 25 · see citing works
Self-citationRisk-Taking Propensity as a Predictor of Induction Onto Naltrexone Treatment for Opioid Dependence
Aklin, W. M., Severtson, S. G., Umbricht, A., Fingerhood, M., Bigelow, G. E., Lejuez, C. W., & Silverman, K. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05807 · Cited by 18 · see citing works
Acquisition of responding with a remifentanil-associated conditioned reinforcer in the rat
Bertz, J. W., & Woods, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3102-0 · Cited by 14 · see citing works
Whiteside, G. T., & Kyle, D. J. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch016 · Cited by 8 · see citing works
Pharmacological Investigation of NOP-Related Ligands as Analgesics without Abuse Liability
Sukhtankar, D. D., & Ko, M. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch018 · Cited by 5 · see citing works
Self-citationTreatment of Pain and Opioid Abuse
Mogali, S., & Comer, S. D. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch004 · Cited by 4 · see citing works
Commentary on the Current Status of Clinically Used Analgesics
Dodds, T. M. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch001 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337 · see citing works
- Authors
- Sukhtankar, D. D., Lagorio, C. H., & Ko, M.-C.
- Affiliations
- Wake Forest University Health Sciences (US)
- University of Wisconsin–Eau Claire (US)
- Corresponding author
- Sukhtankar, Devki D.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 745
- Pages
- 182-189
- ISSN
- 0014-2999 (ISSN-L)
- PMC
- PMC4259829
- OpenAlex
- W1998637918
- Cited by
- 33
- References
- 44
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 6 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 2 · 2015: 3
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (R01-DA032568, R21-DA035359)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Keywords
- nociceptin/orphanin FQ, NOP receptor agonists, self-administration, opioid reinforcement, remifentanil, mu-opioid receptor, naltrexone, intracisternal administration, J-113397, opioid dependence treatment
- MeSH terms
- Remifentanil, Nociceptin Receptor, Animals, Benzimidazoles, Dose-Response Relationship, Drug, Male, Naltrexone, Narcotic Antagonists, Piperidines, Receptors, Opioid, Reinforcement, Psychology, Self Administration, Rats, Sprague-Dawley, Receptors, Opioid, mu, Substance-Related Disorders, Rats, Azabicyclo Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
